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Abstract
Background: There is currently no effective AIDS vaccine, emphasizing the importance of developing alternative therapies.
Recently, a patient was successfully transplanted with allogeneic, naturally resistant CCR5-negative (CCR5D32) cells, setting
the stage for transplantation of naturally resistant, or genetically modified stem cells as a viable therapy for AIDS.
Hematopoietic stem cell (HSC) gene therapy using vectors that express various anti-HIV transgenes has also been
attempted in clinical trials, but inefficient gene transfer in these studies has severely limited the potential of this approach.
Here we evaluated HSC gene transfer of an anti-HIV vector in the pigtailed macaque (Macaca nemestrina) model, which
closely models human transplantation.
Methods and Findings: We used lentiviral vectors that inhibited both HIV-1 and simian immunodeficiency virus (SIV)/HIV-1
(SHIV) chimera virus infection, and also expressed a P140K mutant methylguanine methyltransferase (MGMT) transgene to
select gene-modified cells by adding chemotherapy drugs. Following transplantation and MGMT-mediated selection we
demonstrated transgene expression in over 7% of stem-cell derived lymphocytes. The high marking levels allowed us to
demonstrate protection from SHIV in lymphocytes derived from gene-modified macaque long-term repopulating cells that
expressed an HIV-1 fusion inhibitor. We observed a statistically significant 4-fold increase of gene-modified cells after
challenge of lymphocytes from one macaque that received stem cells transduced with an anti-HIV vector (p,0.02, Student’s
t-test), but not in lymphocytes from a macaque that received a control vector. We also established a competitive
repopulation assay in a second macaque for preclinical testing of promising anti-HIV vectors. The vectors we used were HIV-
based and thus efficiently transduce human cells, and the transgenes we used target HIV-1 genes that are also in SHIV, so
our findings can be rapidly translated to the clinic.
Conclusions: Here we demonstrate the ability to select protected HSC-derived lymphocytes in vivo in a clinically relevant
nonhuman primate model of HIV/SHIV infection. This approach can now be evaluated in human clinical trials in AIDS
lymphoma patients. In this patient setting, chemotherapy would not only kill malignant cells, but would also increase the
number of MGMTP140K-expressing HIV-resistant cells. This approach should allow for high levels of HIV-protected cells in
AIDS patients to evaluate AIDS gene therapy.
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Introduction
AIDS continues to be a serious health problem with an
estimated 33 million people infected worldwide [1]. Highly active
antiretroviral therapy reduces viral loads and morbidity and
mortality from AIDS [2], but the side effects can be severe [3] and
the emergence of drug resistant HIV strains is a problem. Despite
substantial efforts to develop a vaccine [4], there is still no cure [5]
and alternative therapies need to be explored. One approach to
cure AIDS has been by transplantation with genetically-modified
T cells that inhibit HIV replication. Several synthetic genes have
been developed which can inhibit infection or replication of HIV-
1 using a gene therapy approach [6–8]. Clinical trials have been
performed using T cell gene transfer that show efficacy [9], but T
cells have a limited life span in vivo which will likely limit the utility
of this approach. The ability of hematopoietic stem cells (HSCs) to
reconstitute the entire hematopoietic system, including the T cell
repertoire, macrophages, dendritic cells and microglial cells,
suggests they are ideal targets for AIDS gene therapy. The recent
report that allogeneic HSC transplantation with naturally-resistant
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support to this approach as a viable therapeutic option, at least
until an effective vaccine can be developed.
However, the inability to efficiently deliver anti-HIV transgenes
to HSCs has been a major roadblock in clinical trials. In a phase I
clinical trial using bone marrow-derived CD34
+ cells transduced
with a Moloney leukemia virus vector containing a Rev response
element (RRE) decoy short-term marking rates of 0.003–0.01%
and long-term marking rates below 0.001% were obtained [11]. In
another study where mobilized CD34
+ cells were used as targets,
the average long-term marking rates with a Moloney leukemia
virus vector containing a ribozyme were 0.01% to 0.001% [12].
More recently, a large randomized, double-blind, phase 2 gene
transfer clinical trial was conducted in 74 HIV-1-infected adults
who received a tat-vpr-specific anti-HIV ribozyme (OZ1) or
placebo delivered in autologous CD34
+ hematopoietic progenitor
cells. In this trial there were no OZ1-related adverse events but
there was also no statistically significant difference in viral load
between the OZ1 and placebo group at the primary end point.
Again, marking was very low in this study and vector DNA did not
reach the quantifiable range of the assay (0.38% of cells analyzed)
in any blood cell sample at any time point. The authors concluded
that the approach was promising but that improvements to
increase engraftment were needed [13].
We previously established conditions for efficient transduction
of pigtailed macaque (Macaca nemestrina) long-term repopulating
cells using vesicular stomatitis virus glycoprotein (VSV-G)
pseudotyped HIV-based lentiviral vectors [14]. Stable, long-term,
polyclonal high-level gene marking was observed using relatively
low multiplicities of infection (MOI)s, and transgene expression
was detected in all lineages. The high levels of gene transfer
observed are likely due to the absence of a functional TRIM5a in
pigtailed macaques [15]. Pigtailed macaques can be infected with
either SHIV or SIV strains. SHIV is a chimera that contains the
HIV-1 env, rev, tat, and vpu genes on a background of SIVmac, and
infects macaques causing simian AIDS [16]. Infection of pigtailed
macaques with SHIV thus offers an excellent preclinical model to
evaluate AIDS HSC gene therapy using lentiviral vectors.
Here we developed and evaluated lentiviral-based anti-HIV
vectors in the pigtailed macaque (Macaca nemestrina) nonhuman
primate model. The lentiviral vectors we used also contain the
P140K version of the O
6-methylguanine-DNA methyltransferase
(MGMT) gene [17] to increase marking after transplantation. The
P140K MGMT mutant confers resistance to methylating agents
such as temozolomide as well as to nitrosoureas such as BCNU
(bis-chloronitrosourea), and allows for efficient selection at the
stem cell level in large animal models [18–20]. The MGMT
protein is expressed in normal human tissues, so in order to
enhance selection, a potent inhibitor, O
6-benzylguanine (O6BG) is
used to inactivate endogenous MGMT. The mutant P140K gene
is resistant to O6BG [21,22], so that an alkylating agent such as
BCNU or temozolomide used in conjunction with O6BG allows
for efficient selection of transduced HSCs. We evaluated marking
and MGMT-mediated selection of macaque repopulating cells
transduced with an anti-HIV lentiviral vector that expresses a
membrane-bound C46 fusion inhibitor [23]. A competitive
repopulation assay with enhanced green and yellow fluorescent
protein (EGFP/EYFP) markers allowed us to evaluate marking of
a combinatorial anti-HIV vector. The macaque competitive
repopulation model we have developed here allows for a facile
and quantitative assessment of the engraftment potential and also
efficacy of vectors proposed for AIDS gene therapy clinical trials.
Importantly, this approach can be rapidly translated to the
clinic because the vectors we describe here target HIV-1, and
transplantation in this primate model closely models human
transplantation. Additionally, the MGMT selection strategy
should be particularly effective for patients with AIDS lymphoma
who will require an HSC transplant and may also be treated with
the chemotherapy agent, BCNU which could increase marking of
the MGMTP140K anti-HIV vector.
Materials and Methods
Ethics Statement
Healthy juvenile pigtailed macaques (Macaca nemestrina) were
housed at the University of Washington National Primate
Research Center under conditions approved by the American
Association for Accreditation of Laboratory Animal Care. Study
protocols were approved by the Fred Hutchinson Cancer
Research Center (FHCRC) Institutional Review Board and the
FHCRC Institutional Animal Care and Use Committee. All
animals received myeloablative total-body irradiation and received
recombinant human granulocyte colony stimulating factor (rhG-
CSF) and standard supportive care after transplantation. Animals
are monitored closely and animal welfare is assessed on a daily
basis, and if necessary several times a day. This includes veterinary
examinations to make sure animals are not suffering. If animals
experience pain they receive pain medications. If pain can not be
relieved, or if veterinary examination reveals signs of suffering that
cannot be relieved by analgesics, antiemetics, or antibiotic therapy,
animals are euthanized.
Lentiviral anti-HIV MGMT vectors
The lentiviral vector plasmid pRSC-SMPGW contains a spleen
focus forming virus (SFFV) long terminal repeat (LTR)-derived
promoter-driven MGMT transgene and a phosphoglycerate
kinase (PGK) promoter-driven EGFP reporter gene and has
already been described [14]. The C46 anti-HIV transgene that
encodes a partial ORF from the HIV envelope protein
transmembrane subunit spanning from amino acids 628 to 673
of gp41 [23] was inserted 39 to the SFFV promoter using standard
cloning techniques and an internal ribosome entry site (IRES)
derived from the encephalomyocarditis virus was placed 39 to the
C46 transgene and upstream of the MGMT transgene so that the
C46 is expressed from SFFV and MGMT is expressed from an
IRES to create the resulting vector plasmid pRSC-SC46-IMPGW.
The U6 Pol III promoter-driven site I shRNA targeting tat and rev
[24] was inserted 59 to the SFFV promoter of the pRSC-SC46-
IMPGW plasmid to create the vector plasmid pRSC-UsI-SC46-
IMPGW. HIV-based vectors were pseudotyped with VSV-G
envelope and produced by transient transfection of 293T cells and
concentrated 100-fold as previously described [25].
Cell lines
Human 174xCEM cells [26], CEM.NKR-CCR5 cells [27],
HeLa-CD4-LTR-b-gal cells [28] and MAGI-CCR-5 cells [29]
were obtained through the AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, from Dr. Peter
Cresswell, Dr. Alexandra Trkola, Dr. Michael Emerman and Dr.
Julie Overbaugh, respectively. 174xCEM and CEM.NKR-CCR5
cells were cultured in Iscove’s Modified Dulbecco’s Medium, and
human embryonic kidney 293 cells, HeLa-CD4-LTR-b-gal and
MAGI-CCR-5 cells were cultured in Dulbecco’s modified Eagle’s
medium. All cell lines were supplemented with 10% heat-
inactivated FBS, 100 U/ml of penicillin, and 100 mg/ml of
streptomycin and were incubated at 37uC in a 5% CO2
atmosphere.
Macaque AIDS Gene Therapy
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The following viruses, infectious virus plasmids, and cell lines
were obtained through the AIDS Research and Reference
Reagent Program from the following investigators. SHIV KU-1
was obtained from Dr. Opendra Narayan and Dr. Sanjay Joag.
HIV-1 89.6 [30] was obtained from Dr. Ronald Collman. Virus
preparations were titered using HeLa-CD4-LTR-b-gal cells as
previously described [28].
Construction of a mutant lentiviral rev helper plasmid for
efficient production of anti-HIV vectors containing rev-
specific shRNAs
The lentiviral helper plasmid pCMVdeltaR8.74 was first
digested with EcoRI and NotI, then klenow-filled and ligated to
create a smaller 5.3 kb plasmid containing the rev target site. This
plasmid was then PCR amplified using two 59 phosphorylated
primers with synonymous mutations in rev (59-GACGAG-
GAACTCATCAGAACAGTCAGACT-39 and 59- CGACA-
GCGGCGAAGAAGGACGGTAT-39) that formed a junction
within the target rev sequence using the high fidelity Phusion
enzyme (NEB, Ipswitch, MA) following the manufacturer’s
recommendations. Following five cycles of PCR with a lower
annealing temperature of 60uC, the annealing temperature was
then raised to 65 for an additional 25 cycles. The resulting linear
PCR product was ligated and transformed into E. coli. From this
plasmid a 2.2 kb NheI to SalI fragment was shuttled back into
pCMVdeltaR8.74 creating the plasmid pCMVdeltaR8.74-sIM.
The mutated rev target site of pCMVdeltaR8.74-sIM was
sequenced to confirm the presence of the three synonymous
nucleotide changes.
In vitro anti-HIV-1 and SHIV assay
The HIV-1 and SHIV indicator MAGI-CCR-5 [29] cell line
was transduced with lentiviral anti-HIV vectors at an MOI of 2.5.
The cells were sorted by flow cytometry for EGFP expression to
over 98% EGFP-expressing cells. For each vector, polyclonal cell
lines were plated in triplicate and infected with approximately
1000 transducing units of either the dualtropic HIV-1 isolate
(HIV89.6) or the X4 SHIV isolate (KU-1). The MAGI-CCR-5
cells were then evaluated for SHIV and HIV-1 replication
48 hours after infection as described [28]. The fold-reduction in
infected cells was calculated as the number of infected beta-
galactosidase-expressing foci relative to the number of infected
beta-galactosidase-expressing foci for the control vector RSC-
SMPGW, for each anti-HIV vector.
Analysis of transgene expression in vitro and in vivo
The above sorted MAGI-CCR-5 cells were analyzed for C46
expression by trypsinizing 1610
6 cells and washing twice with
Dulbecco’s modified phosphate buffered saline (D-PBS), then
blocking in D-PBS with 5% nonfat milk on ice for 10 minutes.
The volume was brought to 100 ml, and 1 mg of 2F5 antibody was
added(Polymun Scientific,Vienna,Austria)and incubatedon icefor
30 min.The cells werewashed twicewith D-PBS,thenincubatedon
ice for 30 min in 200 ml of a 1:80 dilution of 0.5 mg/ml goat anti-
human secondary antibody conjugated to R-phycoerythrin (Jackson
ImmunoResearch, West Grove, PA) in D-PBS. The cells were
washed twice with D-PBS and analyzed by flow cytometry. For
detection ofsiRNA expression by Northern Blot, transduced MAGI-
CCR-5 cells were sorted to over 98% EGFP-positive cells and total
RNA was isolated using STAT-60 (Tel-Test, Friendswood, TX)
reagent according to the manufacturer’s recommendations. Ten mg
of total RNA was run on a 10% TBE-Urea Ready Gel (Bio-Rad
Laboratories, Hercules, CA) together with a size marker and then
electro-transferred to a Hybond N
+ membrane (GE Healthcare,
Piscataway, NJ). The membrane was baked at 80uC for 2 hours and
then prehybridized for 3 hours at 37uC in QuikHyb hybridization
buffer (Stratagene, La Jolla, CA) with 100 mg/ml final concentration
of salmon sperm DNA. The membrane was then hybridized
overnight in QuikHyb hybridization buffer at 37uCw i t h5p m o lo f
oligonucleotide DNA probe end labeled with c-[
32P]-ATP using 10
units of polynucleotide kinase(Invitrogen, Carlsbad,CA). The tat/rev
site I shRNA probe used was 59-GCGGAGACAGCGACGAA-
GAG-39. After hybridization the membrane was then briefly washed
in 6x SSPE buffer (20X SSPE is 3 M NaCl, 0.2 M NaH2PO4,
0.02 M EDTA, pH 7.4), then exposed using a Molecular Dynamics
Storage Phosphor Screen (GE Healthcare, Piscataway, NJ) for one
week and analyzed using a Typhoon Trio Variable Mode Imager
(GE Healthcare) and ImageQuant TL(GE Healthcare) software.To
evaluate RNA loading the blots were stripped with 1% sodium
dodecyl sulfate at 85uC for 30 min and washed, then hybridized as
described above using a U6 snRNA probe 59-TATG-
GAACGCTTCTCGAATT-39.
For in vivo analysis of C46 mRNA expression total RNA was
isolated from macaque PBMCs using STAT-60 (Tel-Test,
Friendswood, TX, USA) reagent according to manufacturer’s
recommendations. cDNA was synthesized using SuperScript II
Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA) in a
reaction containing 4 ml 5x First-Strand Buffer, 25 mg/ml
Oligo(dT)12–18, 0.5 mM each dNTPs, 10 mM DTT, 40 units
RNaseOUT (Invitrogen), 50 ng total RNA template and H2Ot oa
final volume of 20 ml. cDNA was incubated with RNase H at 37uC
for 20 min prior to real-time PCR. Real-time PCR assay was
performed on a 7500 Real Time PCR System (Applied
Biosystems, Foster City, CA, USA), using QuantiTect SYBR
Green PCR kit (Qiagen, Valencia, CA, USA) in a reaction
containing 2 ml template cDNA, 25 ml 2x QuantiTect SYBR
Green PCR Mastermix, 300 nM of each forward and reverse C46
primers (Forward: 59-CCAGATCTTGGATGGAGTGG–39, Re-
verse: 59-CTGCTCGTTCTTCTCCTGCT-39)o rb-Globin
primers (Forward: 59- CCTATCAGAAAGTGGTGGCTGG-39,
Reverse: 59-TTGGACAGCAAGAAAGTGAGCTT-39) and H2O
to a final volume of 50 ml. Reaction conditions were 50uC for
2 min and 95uC for 15 min (16), then 94uC for 15 sec, 56uC for
30 sec, 72uC for 1 min (406). A final dissociation curve analysis
was performed to detect nonspecific amplification products.
Pigtailed macaque transplantation
Healthy juvenile pigtailed macaques (Macaca nemestrina) were
housed at the University of Washington National Primate
Research Center under conditions approved by the American
Association for Accreditation of Laboratory Animal Care. Study
protocols were approved by the FHCRC Institutional Review
Board and the FHCRC Institutional Animal Care and Use
Committee. The conditions for transplantation have been
described previously [14]. Briefly, animals were administered
rhG-CSF at 100 mg/kg, and also given recombinant human stem
cell factor at 50 mg/kg prior to bone marrow harvest. CD34
+ cells
were enriched by magnetic beads (Miltenyi Biotec, Auburn, CA)
according to the manufacturer’s instructions. All animals received
myeloablative total-body irradiation and received rhG-CSF and
standard supportive care after transplantation.
MGMT-mediated selection of transduced macaque
repopulating cells and in vivo tracking of marked cells
Monkeys received an intravenous infusion of 120 mg/m
2 O6BG
and 45 minutes to 1 hour later received an intravenous infusion of
Macaque AIDS Gene Therapy
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2. An identical dose of O6BG was
given intravenously 8 hours after the end of BCNU infusion [31].
To track marking in vivo, leukocytes were analyzed as previously
described [14]. Briefly, leukocytes isolated by ammonium chloride
red cell lysis from heparinized peripheral blood and bone marrow
samples drawn at multiple time points after transplantation were
analyzed for EGFP/EYFP expression on a FACSVantage or
FACSCanto (Becton–Dickinson, San Jose, CA, USA). The anti-
bodies used for lineage-specific markers included CD3 (clone SP34-
2), CD4 (clone L200), CD8 (clone RPA-T8), CD14 (clone M5E2),
CD13 (clone L138), CD20 (clone L27), and CD34 (clone 563). All
antibodies were supplied by Becton Dickinson (Franklin Lakes, NJ)
and conjugated to phycoerythrin. Quantitative PCR analysis of
marking was performed using primers and probes specific for EGFP
or EYFP as previously described [32].
Ex vivo anti-SHIV assay in macaque hematopoietic
repopulating cell-derived CD4
+ cells
CD4
+ cells were enriched from 20 ml of macaque peripheral
blood from a control animal T04228, which was transplanted with
cells transduced with the control vector RSC-SMPGW and also
from animal M05189, which received cells transduced with the
RSC-SC46-IMPGW vector that expresses the C46 fusion
inhibitor. Peripheral blood CD4
+ cells were isolated using the
Dynal CD4 Positive Isolation Kit (Invitrogen, Carlsbad CA)
following the manufacturer’s instructions. The recovered cells
were cultured in Iscove’s Modified Dulbecco’s Medium (IMDM)
supplemented with 10% fetal bovine serum (FBS) and were
activated by the addition of paramagnetic beads (Dynabeads
M-450 Tosylactivated, Invitrogen, Carlsbad CA) coated with
mouse monoclonal antibodies anti-human CD3 (clone SP34-2 BD
Biosciences, San Jose CA) and anti-human CD28 (CD28.2
obtained from Dr. Daniel Olive, INSERM, France, through the
NIH Nonhuman Primate Reagent Resource). The beads were
prepared according to the manufacturer’s protocol and 1610
7
beads were coated with 0.5 mg of anti-CD3 and 4.5 mg of anti-
CD28. The CD4
+ purified cells were stimulated with 3 beads per
cell and 100 U/ml recombinant human IL-2 (rhIL-2) (Chiron,
Emeryville CA). One day after expansion the cells were plated at
2610
4 cells in a 48-well microplate and mock infected or
challenged with SHIV in triplicate. Replication of SHIV was
confirmed by MAGI-CCR-5 assay as described above. Twelve
days after challenge, the percentage of EGFP expressing cells
(EGFP) in infected and control cultures was determined by flow
cytometry and the relative vector proviral copy number was
determined by real-time PCR using primers specific for the
lentiviral cis-acting region as described previously [14].
Results
Lentiviral anti-HIV MGMT vectors
The control bicistronic lentiviral vector RSC-SMPGW has been
described previously and contains the P140K version of MGMT
for in vivo selection driven from an SFFV promoter, and an EGFP
reporter gene driven from the human PGK promoter [14]. This
vector also contains a safety-modified woodchuck hepatitis virus
post-transcriptional regulatory element to enhance gene expres-
sion in vivo (Figure 1). We chose this configuration because in
previous experiments we have observed efficient MGMT-based
selection at the stem cell level using the SFFV promoter [19,33],
and we have also observed efficient EGFP expression using the
PGK promoter in both myeloid and lymphoid lineages [14,34].
The RSC-SC46-IMPGW vector expresses the C46 membrane-
bound HIV-1 fusion inhibitor. For this C46 transgene, the signal
peptide of the low-affinity nerve growth factor receptor (LNGFR)
directs translocation into the endoplasmic reticulum, and the
human immunoglobulin G2 (IgG2) hinge fused to the human
CD34 membrane-spanning domain serves as a scaffold to anchor
the peptide to the cell surface [23]. High level expression of the
C46 fusion inhibitor is required for a potent antiviral effect [35], so
we expressed C46 from the strong SFFV promoter and expressed
MGMT from an IRES. We chose this configuration because
expression from an IRES (MGMT) leads to lower levels of
expression than the transgene expressed from promoter 59 to the
IRES [36]. Thus higher levels of C46 expression would be
obtained relative to MGMT. Following selection with O6BG and
BCNU, cells expressing lower levels of MGMT should have a
selective disadvantage, and cells surviving BCNU selection might
have even higher levels of C46 than unselected cells. The RSC-
UsI-SC46-IMPGW vector has an additional Pol III-driven tat/rev
specific site I shRNA [37]. The lentiviral vectors are based on the
RRL vector system and are self-inactivating (SIN) and contain a
central polypurine tract [38]. For these studies we chose two anti-
HIV transgenes that inhibit both HIV-1 and SHIV, so anti-HIV
vectors would be expected to have similar efficacy inhibiting SHIV
in our macaque studies and inhibiting HIV-1 in potential future
clinical applications. The C46 targets HIV-1 env and the site I
shRNA targets HIV-1 tat and rev which are all in the SHIV
chimera and required for SHIV replication.
Lentiviral anti-HIV vectors potently inhibit SHIV and HIV-1
infection
We first compared the ability of the two anti-HIV vectors to
inhibit SHIV and also HIV-1 using a single-cycle infection assay.
In this assay the indicator MAGI-CCR-5 cell line was transduced
Figure 1. Lentiviral anti-HIV vectors. The lentiviral vector RSC-SMPGW contains an SFFV promoter (S) driving expression of the P140K mutant of
MGMT (M) and also contains a human PGK promoter (P) driving expression of EGFP (G). This vector also contains a safety modified woodchuck
hepatitis virus post transcriptional regulatory element (W). The following anti-HIV transgenes were added to this vector; the transmembrane-localized
C46 HIV envelope fusion inhibitor expressed from the SFFV promoter with an IRES expressing MGMT (RSC-SC46-IMPGW), and the U6 driven tat/rev
site I shRNA combined with the C46-expressing vector (RSC-UsI-SC46-IMPGW). The long terminal repeats (LTR) and lentiviral cis-acting region (CAR)
are also indicated.
doi:10.1371/journal.pone.0007693.g001
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cytometry for EGFP expression to over 98% percent EGFP-
expressing cells. For each vector these polyclonal cell lines were
challenged in triplicate with either SHIV or HIV-1 and infection
was evaluated 48 hours after infection. The MAGI-CCR-5 cell
line detects both SHIV and HIV infection, so this approach
allowed us to quantitatively compare the relative ability of each
vector to inhibit either HIV-1 or SHIV during only one round of
infection. The fold-reduction in infected cells is reported relative to
the control vector RSC-SMPGW for each vector (Figure 2). In
this single-cycle infection test, the lentiviral vector expressing C46
provided approximately 1800-fold and 2500-fold inhibition of
HIV-1 and SHIV replication, respectively. The lentiviral vector
that also contained the U6-driven tat/rev shRNA inhibited both
HIV-1 and SHIV replication to a lesser extent, 66-fold and 50-
fold, respectively. For both vectors the difference between
inhibition of HIV-1 and inhibition of SHIV was not significant
(p=0.49, p=0.35) as would be expected since these vectors target
HIV-1 tat, rev and env that are in both HIV-1 and also in SHIV.
We also evaluated the effect of inclusion of multiple anti-HIV
transgenes on the individual genes (Figure 3). We found that
adding the U6-driven site I tat/rev shRNA decreased C46
expression, consistent with our findings that the combinatorial
vector RSC-UsI-SC46-IMPGW was not as effective as RSC-
SC46-IMPGW in the SHIV and HIV-1 inhibition assay.
Conversely, the C46 transgene did not affect expression of the
U6-driven site I shRNA as assessed by Northern blot.
Development of a lentiviral helper plasmid with a
modified rev for production of lentiviral vectors which
express the site I tat/rev shRNA
Lentiviral vectors can be produced at high titer and mediate
efficient transduction of human hematopoietic repopulating cells
in murine xenotransplantation assays [39] and also canine [25]
and pigtailed macaque repopulating cells [14]. However, one
challenge of using lentiviral vectors for AIDS gene therapy is that
anti-HIV transgenes that interfere with HIV-1 replication steps
required for efficient HIV-based lentiviral vector production can
severely reduce titers [40,41]. We were able to produce the anti-
HIV lentiviral vector containing the C46 transgene RSC-SC46-
IMPGW at high titer; however, the titers were drastically reduced
for the RSC-UsI-SC46-IMPGW vector, which contains the tat/rev
shRNA expression cassette. The lentiviral vectors we used are
pseudotyped with VSV-G, so the C46 transgene which inhibits
fusion between the HIV-1 envelope glycoprotein and the cell
membrane would not be expected to reduce lentiviral vector titers,
and did not. However, the site I tat/rev shRNA, targets rev, and Rev
protein is required for efficient production of lentiviral vector
virions, likely explaining the low titers of the site I tat/rev shRNA.
The titer of foamy vector virions that contain this tat/rev shRNA is
not adversely affected [42], so we reasoned that knockdown of
lentiviral vector RNAs by cleavage of the shRNA target in the
Figure 2. Inhibition of HIV-1 and SHIV in vitro. The anti-HIV
vectors were evaluated for SHIV and HIV-1 inhibition using a single-
cycle replication assay where MAGI-CCR-5 cells were transduced with
the indicated vectors, sorted to over 98% EGFP-positive, then
challenged with the indicated viruses and tested for virus replication
48 hours after challenge. The fold-reduction in detected infectious units
is reported for each vector relative to the control vector RSC-SMPGW
that does not contain an anti-HIV transgene.
doi:10.1371/journal.pone.0007693.g002
Figure 3. Effect of multiple components on expression of
individual anti-HIV transgenes. (A) Expression of the membrane-
bound C46 fusion inhibitor was detected by antibody staining in
transduced MAGI-CCR-5 cells. Cells transduced with either a control
vector RSC-SMPGW that does not express C46, or the C46 vector RSC-
SC46-IMPGW, or the U6-driven site I shRNA and C46 vector RSC-UsI-
SC46-IMPGW were sorted to over 98% EGFP-positive cells and stained
using a primary C46 monoclonal and a secondary phycoerythrin-
conjugated antibody. Expression of the C46 transgene is greatly
reduced in cells transduced with the vector that also expresses the U6-
driven site I tat/rev shRNA. (B) Expression of the U6-driven site I tat/rev
shRNA was compared by Northern blot in MAGI-CCR-5 cells using a tat/
rev site I-specific probe (top panel). NTC is non-transduced control,
EGFP is cells transduced with a lentiviral vector that only expressed
EGFP, UsI is cells transduced with a vector that expresses EGFP and the
U6-driven site I shRNA, C46 is the vector RSC-SC46-IMPGW, UsI+C46 is
the vector RSC-UsI-SC46-IMPGW. The arrow indicates approximately 21
nt. Expression of the U6-driven site I tat/rev shRNA was not affected by
the addition of a C46 transgene. The bottom panel is a loading control
with a U6 snRNA probe hybridized to the same blot.
doi:10.1371/journal.pone.0007693.g003
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titers observed since this mechanism would also be expected to
reduce foamy vector titers. Instead, we considered that the main
mechanism may be knockdown of Rev function [43] or of Gag-Pol
helper function via shRNA-mediated degradation of helper
plasmid transcripts that include the rev target sequence. The
lentiviral helper plasmid pCMVRdelta8.74 produces Gag, Pol,
and Rev which are all required for production of lentiviral vector
virions. The tat/rev shRNA target sequence is located on both gag-
pol and on rev mRNAs so we reasoned that inserting a synonymous
mutation in rev that would alter the shRNA target on the lentiviral
helper plasmid, but would not change the Rev ORF, might
increase titers. A 3 bp synonymous mutation was incorporated in
rev at the site I in pCMVRdelta8.74 helper plasmid (Figure 4A),
and the resulting helper plasmid was named pCMVRdelta8.74-
sIM. When we produced the tat/rev shRNA containing vector,
RSC-UsI-SC46-IMPGW, using this helper plasmid with the
mutated site I rev, the vector titers increased 38-fold (Figure 4B).
The titer of the control vector RSC-SMPGW was slightly
decreased (13%), suggesting the rev mutation minimally impaired
the efficiency of lentiviral vector production. Using the
pCMVRdelta8.74-sIM helper plasmid, we were able to produce
the tat/rev shRNA-containing lentiviral vector RSC-UsI-SC46-
IMPGW at unconcentrated titers in excess of 10
5 and at titers in
excess of 10
7 transducing units/ml after 100-fold concentration,
titers sufficient for experiments in large animal models and also for
clinical studies.
Transduction and engraftment of lentiviral anti-HIV
vectors in the pigtailed macaque
In order to translate an AIDS gene therapy approach to the
clinic, it is important to determine if the proposed anti-HIV
transgenes might have a deleterious effect on hematopoietic stem
cell engraftment and differentiation. We have previously shown
that the pigtailed macaque (M. nemestrina) is an excellent model to
evaluate lentiviral HSC gene therapy strategies because high level
marking in multiple hematopoietic lineages can be obtained [14],
likely due to the absence of TRIM5a restriction [15]. We have
previously demonstrated efficient marking into myeloid and
lymphoid lineages using the control vector RSC-SMPGW [14],
so we performed two transplants with the anti-HIV vectors. The
pre-transplant marking and engraftment data for these two
animals is shown in Table 1. The first transplant was with the
RSC-SC46-IMPGW vector that expresses the C46 membrane-
bound HIV-1 fusion inhibitor. In this animal (M05189) once
marking had stabilized, approximately 5% and 4% of granulocytes
and lymphocytes were gene-modified as determined by EGFP
expression (Figure 5). Marking was slightly lower than what we
had achieved previously in two other macaques using the RSC-
SMPGW control vector, which does not have an anti-HIV cassette
[14] but was still significant and stable.
In the second transplant we employed a competitive repopu-
lation approach where the anti-HIV vector RSC-UsI-SC46-
IMPGW that expresses EGFP was evaluated with a second
experimental arm using the control vector RSC-PYW that
expresses only EYFP. Macaque CD34
+ cells were separated into
two experimental arms with equal numbers of CD34
+ cells that
were exposed to each vector separately. Following the ex vivo
exposure to the vector preparations, the cells were washed
extensively and then re-infused sequentially so that macaque
repopulating cells can be marked with either vector, but not with
both. This approach allowed us to evaluate the relative marking
between the control EYFP and the anti-HIV EGFP vector in the
same macaque, thereby eliminating inter-animal variability. It is
important to note that, since each experimental arm represents
only one-half of the infused cells, the marking observed for each
individual arm is only one-half of what would be expected if the
transplant were performed using only a single vector. For example,
Figure 4. Production of tat/rev shRNA-containing lentiviral
vectors at high titer using a modified helper plasmid. (A) Three
synonymous mutations indicated by an underline were introduced into
rev in the lentiviral helper plasmid pCMVRdelta8.74 which expresses
Gag-Pol and Rev to create pCMVRdelta8.74-sIM, which contains three
mismatches at the tat/rev site I shRNA target sequence. (B) Lentiviral
vectors were prepared by transient transfection using either the
lentiviral helper plasmid pCMVRdelta8.74, which contains the wild-type
rev sequence (wt-rev), or the pCMVRdelta8.74-sIM helper, which
contains the mutated (sIM-rev) and titered using the EGFP reporter.
The RSC-UsI-SC46-IMPGW vector containing the tat/rev shRNA is
produced at low titer using the wt rev helper, but is produced at 38-
fold higher titer using the sIM-rev helper.
doi:10.1371/journal.pone.0007693.g004
Table 1. Lentiviral transduction and engraftment of pigtailed macaque CD34
+ cells.
Monkey*
CD34+
Purity
No. of CD34-enriched
cells/kg 610
6 before
culture Transgenes
No. of
infused
cells/kg 610
6 MOI
{
Pre-infusion
transduction
efficiency
{
Days to
ANC .500
Days to
platelets
.20,000
M05189 (4.8 kg) 95% 48.5 C46, MGMT 22.7 5 49.7% 17 34
M05270 (4.8 kg) 94% 30 EYFP 34.2 2 20.6% .150 18
30 EGFP, MGMT, U6shI, C46 40.4 2 6.28%
*Monkey and weight at time of transplantation in brackets.
{Multiplicity of infection based on titer determined by transduction of HT1080 cells.
{Percentage of fluorescence-positive cells assessed by flow cytometry for EGFP or EYFP in liquid cultures on day 11 (M05270) or 6 (M05189) after transduction.
doi:10.1371/journal.pone.0007693.t001
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which was approximately 4.5% after marking stabilized (30 to 120
days), would be expected to be approximately 9% if this were the
only vector used. Thus, the marking level in the control EYFP
experimental arm of M05270 closely matched what we observed
in macaque M05189, which received the vector that expresses the
C46 transgene and MGMT in addition to the EGFP transgene.
For the EGFP-expressing anti-HIV vector arm of macaque
M05270, we observed much lower marking in granulocytes,
approximately 0.6%. The marking in lymphocytes gradually rose
to a plateau for both M05189 and for the control EYFP arm in
animal M05270. This slow rise in lymphocyte marking was similar
to what we have previously observed for animals with no anti-HIV
transgene cassette [14].
The pre-transplant marking (Table 1) for macaque M05270
showed there was an approximately 3.3-fold lower marking rate
for the EGFP-positive anti-HIV vector relative to the control
EYFP-positive vector, despite being matched for MOI based on
transduction in HT1080 cells. In vivo, marking with the anti-HIV
vector was approximately 7.5-fold lower than the control EYFP
arm. Analysis of the marking in vivo in M05270 by quantitative
PCR confirmed the lower marking in the EGFP anti-HIV arm,
with 11.4-fold lower marking relative to the control arm, showing
that the difference was not due to silencing of the anti-HIV vector.
The approximately two-fold loss in gene-marking from pre-
transplant levels to marking in repopulating cells and the overall
7.5 fold lower transduction rate in macaque repopulating cells
relative to transduction of the HT1080 cells used to determine the
titer of vector preparations suggests there may be a deleterious
effect of the U6-driven site I tat/rev shRNA in primate
repopulating cells. For the RSC-UsI-SC46-IMPGW vector,
marking in lymphocytes remained low until day 111 after
transplantation and then increased slightly to match marking in
granulocytes.
The relative marking levels in myeloid (CD13, CD14) or
lymphoid (CD3, CD4, CD8, and CD20) subsets and also in bone
marrow CD34
+ cells was also evaluated (Figure 6). The EGFP
marker allowed us to accurately assess marking in myeloid and
lymphoid lineages. For macaque M05189 that received the
membrane-bound C46 HIV-1 fusion inhibitor, relatively high
marking levels were detected in all lineages examined. There was
no obvious difference in the relative marking in these lineages
compared to historical control macaques [14] that received the
RSC-SMPGW vector, providing strong evidence that the C46
transgene does not have any obvious lineage-specific effects on
differentiation. We confirmed expression of the C46 in vivo in
peripheral blood from monkey M05189 by real-time reverse
transcriptase PCR. The data showed 12.6-fold higher expression
Figure 5. Transgene expression levels in peripheral blood cells
of macaques and MGMT-mediated in vivo selection using
O6BG and BCNU. The percentages of EGFP and EYFP-expressing
leukocytes detected by flow-cytometry are shown for monkeys M05189
(A) and M05270 (B). Granulocytes and lymphocytes were gated based
on forward and side-scatter properties and the percentage of EGFP or
EYFP-expressing gated cells is shown. Administration of O6BG and
BCNU to macaque M05189 is indicated by an arrow. For animal M05270
the control arm vector transduced cells are shown with back diamonds
connected by a solid line (granulocytes) or dotted line (lymphocytes),
and anti-HIV vector RSC-UsI-SC46-IMPGW transduced cells are shown by
open boxes connected by a solid line (granulocytes) or dotted line
(lymphocytes).
doi:10.1371/journal.pone.0007693.g005
Figure 6. Flow-cytometric analysis of transgene-expressing
cells in peripheral blood subpopulations and bone marrow
CD34
+ cells. (A) Displayed is the percentage of transgene positive cells
in different leukocyte subpopulations in the peripheral blood of
monkey M05189 that received the C46 membrane fusion inhibitor
and EGFP-expressing vector. In this macaque EGFP-expressing cells
were found at significant percentages in all lineages examined. (B)
Lineage-specific staining for macaques M05189 and M05270. Macaque
M05189 and the control EYFP arm of M05270 had significant
percentages of transgene-expressing cells in all lineages. For the
experimental EGFP-expressing arm of M05270 that received the vector
with the C46 fusion inhibitor and the U6-driven site I shRNA, the
percentage of transgene-expressing cells was low in all lineages
examined.
doi:10.1371/journal.pone.0007693.g006
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to sorted EGFP-negative cells. Analysis of C46 mRNA expression
in EGFP positive or negative cells from the control monkey
T04228 that received the control vector RSC-SMPGW showed
only background levels. For macaque M05270 the marking level
for the control EYFP arm was relatively high in all lineages
examined, but marking for the EGFP-expressing anti-HIV vector
was much lower in all lineages examined.
MGMT-mediated increase in marking of a lentiviral anti-
HIV vector
The MGMT cassette in the anti-HIV vectors provides a means
to increase marking after transplantation. The P140K mutant
MGMT is not sensitive to the inhibitor O6BG, which is used to
inactivate endogenous MGMT. The alkylating agent BCNU is
toxic to cells that do not express MGMT, so in the presence of
both agents cells that do not express the mutant P140K MGMT
are killed resulting in an increase in the percentage of marked
EGFP-expressing cells. We treated macaque M05189 with O6BG
and BCNU in an attempt to increase marking with the anti-HIV
vector that expresses the C46 fusion inhibitor. We observed a large
but transient increase in marking in granulocytes that began to
stabilize at approximately 9% up from a pre-transplant marking at
approximately 4–5% (Figure 5). Following the treatment the
marking in lymphocytes slowly increased from approximately 4%
to approximately 7%.
Protection of macaque lymphocytes from SHIV infection
after HSC transplantation
The goal of AIDS gene therapy is to provide patients with
mature HIV-resistant immune cells derived from repopulating
HSCs. To be effective, mature immune cells differentiated in vivo
from long-term hematopoietic repopulating cells must retain their
resistance to viral infection. To evaluate the viral resistance of
immune cells differentiated in vivo, we isolated CD4
+ lymphocytes
from macaque M05189 peripheral blood and challenged these
cells with SHIV ex vivo. We isolated and challenged CD4
+ cells
after MGMT-mediated selection when marking in lymphocytes in
M05189 had risen to 7%, reasoning that this should provide a
sufficient percentage of EGFP-positive cells to observe an
enrichment if cells were protected during an ex vivo challenge.
As a control we isolated peripheral blood cells from a previously
described control macaque T04228 [14] that was transplanted
with cells transduced with the RSC-SMPGW vector that does not
contain an anti-HIV transgene. T04228 had also been previously
treated with O6BG and BCNU to increase marking. Macaque
lymphocytes were stimulated with beads coated with CD3 and
CD28 antibody and challenged at an MOI of 0.05 in triplicate.
Twelve days later the percentage of EGFP cells was determined
and the fold-increase in the percentage of cells expressing EGFP
was determined relative to a mock-infected culture to determine if
EGFP-expressing cells with the anti-HIV vector cells had been
protected and therefore enriched (Figure 7). We observed a
statistically significant (p,0.02) 4-fold increase in EGFP-express-
ing cells in challenged cells from macaque M05189 that also
expressed the C46 HIV fusion inhibitor but not in cells from the
control macaque T04228. The percentage of EGFP-expressing
cells increased from 8.3% to 33%. DNA was isolated from these
cultures and real-time PCR was performed using a lentiviral
vector-specific primer and probe set to verify the enrichment of
gene-modified cells. Analysis of the relative proviral vector content
between mock-challenged and challenged cells confirmed that
there was a statistically significant (p,0.01) enrichment of gene-
modified cells in the challenged cultures for M05189 but not for
the control macaque T04228. Thus we have shown that mature
lymphocytes derived from long-term repopulating cells can be
selected using MGMT and are protected from challenge.
Discussion
Here we developed lentiviral anti-HIV vectors that also contain
a P140K MGMT transgene cassette and evaluated these vectors in
in vitro studies and also in a clinically relevant primate model for
AIDS gene therapy. We found that vectors containing a C46 HIV
fusion inhibitor did not adversely affect the lentivirus titer, but that
the addition of an anti-HIV siRNA transgene led to significant
reduction in titer. To overcome the dramatic reduction in the titer
of anti-HIV siRNA lentivirus vectors, we developed a modified rev
helper plasmid that allows for high titer lentivirus preparations
containing anti-HIV siRNA transgenes. Using fluorescent markers
we were able to accurately track marking in vivo. We observed
efficient gene transfer using a lentiviral vector that expresses a
membrane-anchored HIV-1 fusion inhibitor and demonstrated
that lymphocytes that are differentiated in vivo from engrafted
hematopoietic repopulating cells transduced with this anti-HIV
vector were protected from SHIV infection.
HSC gene therapy has the potential to inhibit the progression
of, or potentially cure AIDS. However, obtaining efficient gene
delivery to HSCs has been a roadblock for this field, so developing
means for efficient gene transfer of anti-HIV transgenes to HSCs is
an important step towards the goal of an effective AIDS gene
therapy. There are several models for HIV gene therapy including
mouse xenotransplantation models [44,45]. However, viral
replication and AIDS are best modeled in nonhuman primates
where several of the pathological consequences of AIDS can be
reproduced. Simian AIDS pathology includes high viral load in
the peripheral circulation, hematopoietic abnormalities and loss of
CD4
+ lymphocytes in the peripheral blood, and in the gut-
associated lymphoid tissue. In the SHIV macaque model the
Figure 7. Macaque repopulating CD4
+ lymphocytes that
express the C46 fusion inhibitor are protected from SHIV
infection as evidenced by enrichment of transduced cells
during ex vivo challenge. CD4-enriched peripheral blood lympho-
cytes from macaque T04228 transplanted with CD34
+ cells transduced
with the control EGFP expressing vector RSC-SMPGW (Control
macaque) or macaque M05189 transduced with the lentiviral C46 and
EGFP expressing vector RSC-SC46-IMPGW (C46 Macaque) were either
mock infected or challenged with SHIV in triplicate. Twelve days after
challenge the percentage of EGFP expressing cells (EGFP) in infected
and control cultures was determined by flow cytometry. The relative
vector proviral copy number (Vector DNA) was also determined by real-
time PCR to assess the enrichment of transduced cells in infected
cultures. Standard error and p values from a Student’s t test are shown.
doi:10.1371/journal.pone.0007693.g007
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extends to encephalitis and other organ-specific disease [16].
Because of these advantages the nonhuman primate AIDS model
has played a crucial role in the development of anti-HIV treatment
strategies [46-48]. In the SHIV macaque model, unlike the human
population, the timing of infection can be controlled, and findings
can be quantified and directly correlated with disease under
controlled conditions. For these reasons the SHIV-macaque model
is also an excellent model to study AIDS gene therapy strategies.
The competitive repopulation assay we describe here using EGFP
and EYFP fluorescent markers has allowed us to compare marking
across multiple hematopoietic lineages.
Lentiviral vectors have several advantages for HSC gene
therapy including the fact that they transduce quiescent cells
more efficiently than gammaretroviral vectors and they can be
produced at high titer in a self-inactivating (SIN) configuration
[49]. Lentiviral vectors may also be safer than gammaretroviral
vectors [50] based in part on differences in their integration profile
[51,52]. One disadvantage of using HIV-1 based lentiviral vectors
for AIDS gene therapy is that some anti-HIV transgenes that
target components of HIV involved in vector production can
reduce vector titers [40,41]. This is generally not a problem for in
vitro studies or mouse studies where a limited number of target
cells need to be transduced. However, for preclinical monkey
studies or for clinical trials, obtaining high titers is critical to
establishing high marking levels. Here we show that mutating the
lentiviral helper plasmid by making a synonymous mutation in rev
allowed for production of a high titer combinatorial HIV-based
lentiviral anti-HIV vector containing a potent anti tat/rev shRNA.
Importantly, this allowed us to generate large-scale vector
preparations with this anti tat/rev vector at a titer sufficient to
perform primate transplantation experiments.
Stable resistance to SHIV replication is a prerequisite for an
effective gene therapy, but it is also critical that the transgene does
not impair engraftment or differentiation of transplanted HSCs. We
obtained high levels of engraftment in a monkey model with the
C46 membrane-bound fusion inhibitor. For this vector there were
no obvious differences in EGFP expression between myeloid or
lymphoid lineages or within subsets of cell types within these
lineages, suggesting that the C46 fusion inhibitor should also be safe
for use in a clinical setting. Conversely, we observed low marking
when the anti-HIV vector also contained a shRNA driven by a U6
Pol III promoter. Our in vivo data are consistent with data reported
by An et al. [53] where expression of shRNAs from the U6 Pol III
promoter inhibited the expansion of primate lymphocytes in vitro.
The anti-HIV vectors that we developed here also contain the
P140K mutant MGMT transgene to allow for in vivo selection. We
have previously shown that MGMT supports efficient in vivo
selection of HSCs in large animal models [18,19]. Here we show in
the macaque that gene marking of an anti-HIV vector can be
increased in both myeloid and lymphoid populations. Although we
have only shown protection in one macaque we have established
that stable MGMT-mediated selection is reproducible in other
monkeys (H-P. Kiem and G.D. Trobridge, unpublished data). Thus
we believe this approach to increase the percentage of protected
cells in vivo will likely be reproducible, and this model will be a
powerful way to test anti-HIV vectors prior to clinical trials.
Treatment-associated abnormalities associated with O6BG and
BCNU were minimal with transient transaminitis that resolved
quickly following treatment. Thissuggests that MGMT-mediated in
vivo selection of anti-HIV gene-modified cells should be well
tolerated, and HIV patients who suffer from HIV-associated
lymphoma in particular could benefit from this approach.
Importantly, we show that following engraftment, MGMT
selection, and differentiation in vivo, these cells were protected
from SHIV infection. The P140K MGMT is thus a very useful tool
in this model that has allowed us to increase the marking in vivo.
Using this strategy, marking could be further increased with
additional O6BG and BCNU treatments, and monkeys could be
challenged with SHIV. These studies should be highly informative
to establish a proof-of-concept for AIDS gene therapy, and will
facilitate evaluation and improvement of vectors being considered
for clinical applications. Using the competitive repopulation model
we describe here, we plan to test additional combinatorial vectors
we have recently constructed that contain H1 Pol III and also Pol II
promoters for shRNA expression which may be safer in terms of off-
target effects on endogenous microRNAs [53-55]. An important
feature of the SHIV pigtailed macaque model is that anti-HIV-1
transgenes can be assessed, so efficacy in this model should translate
well to clinical studies. Additionally, because of the defective
TRIM5a in the pigtailed macaque, we were able to use HIV-
derived vectors that efficiently transduce human CD34
+ cells, unlike
SIV-derived vectors [56]. Thus, after removing the PGK-EGFP
cassette from a vector with demonstrated efficacy, we plan to
evaluate the vector in a clinical setting of AIDS lymphoma. After
transplantation with transduced cells, treatment with O6BG and
BCNU would not only have an anti-leukemic effect but should also
increase the number of cells protected from HIV-1.
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